128 related articles for article (PubMed ID: 32041739)
1. First EZH2 Inhibitor Approved-for Rare Sarcoma.
Cancer Discov; 2020 Mar; 10(3):333-334. PubMed ID: 32041739
[TBL] [Abstract][Full Text] [Related]
2. Tazemetostat: EZH2 Inhibitor.
Straining R; Eighmy W
J Adv Pract Oncol; 2022 Mar; 13(2):158-163. PubMed ID: 35369397
[TBL] [Abstract][Full Text] [Related]
3. Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma.
Tansir G; Rastogi S; Shamim SA; Barwad A
Future Sci OA; 2021 Jan; 7(4):FSO675. PubMed ID: 33815821
[TBL] [Abstract][Full Text] [Related]
4. Rare Tumors in Kids May Respond to Tazemetostat.
Cancer Discov; 2018 Jan; 8(1):OF5. PubMed ID: 29141919
[TBL] [Abstract][Full Text] [Related]
5. Epithelioid Sarcoma-From Genetics to Clinical Practice.
Czarnecka AM; Sobczuk P; Kostrzanowski M; Spalek M; Chojnacka M; Szumera-Cieckiewicz A; Rutkowski P
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751241
[TBL] [Abstract][Full Text] [Related]
6. HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.
Lopez G; Song Y; Lam R; Ruder D; Creighton CJ; Bid HK; Bill KL; Bolshakov S; Zhang X; Lev D; Pollock RE
Mol Cancer Res; 2016 Jan; 14(1):35-43. PubMed ID: 26396249
[TBL] [Abstract][Full Text] [Related]
7. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.
Touati N; Schöffski P; Litière S; Judson I; Sleijfer S; van der Graaf WT; Italiano A; Isambert N; Gil T; Blay JY; Stark D; Brodowicz T; Marréaud S; Gronchi A
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):448-454. PubMed ID: 29550245
[TBL] [Abstract][Full Text] [Related]
8. Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft.
Stacchiotti S; Zuco V; Tortoreto M; Cominetti D; Frezza AM; Percio S; Indio V; Barisella M; Monti V; Brich S; Astolfi A; Colombo C; Pasquali S; Folini M; Gounder MM; Pantaleo MA; Collini P; Dei Tos AP; Casali PG; Gronchi A; Zaffaroni N
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31331120
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
10. Positive Results for Tazemetostat in Follicular Lymphoma.
Cancer Discov; 2018 Aug; 8(8):OF3. PubMed ID: 29980507
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
12. Orbital Epithelioid Sarcoma: A Case Report.
Jurdy LL; Blank LE; Bras J; Saeed P
Ophthalmic Plast Reconstr Surg; 2016; 32(2):e47-8. PubMed ID: 25025387
[TBL] [Abstract][Full Text] [Related]
13. Successful Treatment with Pazopanib for Multiple Lung Metastases of Inguinal Epithelioid Sarcoma: A Case Report.
Irimura S; Nishimoto K; Kikuta K; Nakayama R; Susa M; Horiuchi K; Nakamura M; Matsumoto M; Morioka H
Case Rep Oncol; 2015; 8(3):378-84. PubMed ID: 26500539
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
[TBL] [Abstract][Full Text] [Related]
15. Primary Epithelioid Sarcoma of Orbit: A Case Report and Review of the Literature.
Kaya EA; Broadbent TJ; Thomas CJ; Wagner AE; Thatcher SH; Lamoreaux WT; Fairbanks RK; Lee CM
Case Rep Oncol Med; 2018; 2018():3989716. PubMed ID: 30652038
[TBL] [Abstract][Full Text] [Related]
16. Vulvar epithelioid sarcoma in pregnancy.
Moore RG; Steinhoff MM; Granai CO; DeMars LR
Gynecol Oncol; 2002 Apr; 85(1):218-22. PubMed ID: 11925150
[TBL] [Abstract][Full Text] [Related]
17. Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.
Liu Q; Kan Y; Zhao Y; He H; Kong L
Int J Clin Exp Pathol; 2015; 8(11):15328-32. PubMed ID: 26823889
[TBL] [Abstract][Full Text] [Related]
18. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
Andrick BJ; Gandhi A
Ann Pharmacother; 2017 Dec; 51(12):1090-1098. PubMed ID: 28778132
[TBL] [Abstract][Full Text] [Related]
19. Enhancer of zeste homolog 2 (EZH2) inhibitors.
Gulati N; Béguelin W; Giulino-Roth L
Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
